Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy
Systemic lupus erythematosus (SLE) is a typical autoimmune disease; although severe disease and refractoriness to existing therapies are still experienced, the number of cases resistant to remission induction has decreased with the establishment of various therapies. However, improving long-term pro...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2024.2447629 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846106693859016704 |
|---|---|
| author | Satoshi Suzuki Tomoya Otani Keigo Ikeda Naoto Tamura Shinji Morimoto |
| author_facet | Satoshi Suzuki Tomoya Otani Keigo Ikeda Naoto Tamura Shinji Morimoto |
| author_sort | Satoshi Suzuki |
| collection | DOAJ |
| description | Systemic lupus erythematosus (SLE) is a typical autoimmune disease; although severe disease and refractoriness to existing therapies are still experienced, the number of cases resistant to remission induction has decreased with the establishment of various therapies. However, improving long-term prognosis remains a challenge due to the unavoidable prolonged use of non-selective glucocorticoids. To investigate the additional effect of belimumab in the chronic phase, we included 28 of 46 patients with SLE who were initiated on belimumab between January 2018 and October 2022 for glucocorticoid reduction. The efficacy of tacrolimus and mycophenolate mofetil in combination with belimumab was also compared. In the stable chronic phase, the combination with belimumab improved the SLE Disease Activity Index and reduced glucocorticoid requirement. The tacrolimus with belimumab group was not significantly inferior to the mycophenolate mofetil with belimumab group and was effective in treatment and glucocorticoid sparing including cases at all phases of SLE. To improve the long-term prognosis of SLE, it is crucial to introduce highly selective biological agents and reduce glucocorticoids whenever possible. Belimumab is effective with or without hydroxychloroquine and Tac was effective as concomitant drugs. |
| format | Article |
| id | doaj-art-3e0d165ab7fa46c680315bf848e8d1d0 |
| institution | Kabale University |
| issn | 2578-5826 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj-art-3e0d165ab7fa46c680315bf848e8d1d02024-12-27T10:43:13ZengTaylor & Francis GroupImmunological Medicine2578-58262024-12-011710.1080/25785826.2024.2447629Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapySatoshi Suzuki0Tomoya Otani1Keigo Ikeda2Naoto Tamura3Shinji Morimoto4Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Urayasu, JapanDepartment of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Urayasu, JapanDepartment of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Urayasu, JapanDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, JapanDepartment of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Urayasu, JapanSystemic lupus erythematosus (SLE) is a typical autoimmune disease; although severe disease and refractoriness to existing therapies are still experienced, the number of cases resistant to remission induction has decreased with the establishment of various therapies. However, improving long-term prognosis remains a challenge due to the unavoidable prolonged use of non-selective glucocorticoids. To investigate the additional effect of belimumab in the chronic phase, we included 28 of 46 patients with SLE who were initiated on belimumab between January 2018 and October 2022 for glucocorticoid reduction. The efficacy of tacrolimus and mycophenolate mofetil in combination with belimumab was also compared. In the stable chronic phase, the combination with belimumab improved the SLE Disease Activity Index and reduced glucocorticoid requirement. The tacrolimus with belimumab group was not significantly inferior to the mycophenolate mofetil with belimumab group and was effective in treatment and glucocorticoid sparing including cases at all phases of SLE. To improve the long-term prognosis of SLE, it is crucial to introduce highly selective biological agents and reduce glucocorticoids whenever possible. Belimumab is effective with or without hydroxychloroquine and Tac was effective as concomitant drugs.https://www.tandfonline.com/doi/10.1080/25785826.2024.2447629BelimumabSLEtacrolimusmycophenolate mofetilchronic phase |
| spellingShingle | Satoshi Suzuki Tomoya Otani Keigo Ikeda Naoto Tamura Shinji Morimoto Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy Immunological Medicine Belimumab SLE tacrolimus mycophenolate mofetil chronic phase |
| title | Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy |
| title_full | Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy |
| title_fullStr | Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy |
| title_full_unstemmed | Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy |
| title_short | Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy |
| title_sort | additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy |
| topic | Belimumab SLE tacrolimus mycophenolate mofetil chronic phase |
| url | https://www.tandfonline.com/doi/10.1080/25785826.2024.2447629 |
| work_keys_str_mv | AT satoshisuzuki additionalbenefitsofbelimumabinchronicphaseofsystemiclupuserythematosusandefficacyoftacrolimuscombinationtherapy AT tomoyaotani additionalbenefitsofbelimumabinchronicphaseofsystemiclupuserythematosusandefficacyoftacrolimuscombinationtherapy AT keigoikeda additionalbenefitsofbelimumabinchronicphaseofsystemiclupuserythematosusandefficacyoftacrolimuscombinationtherapy AT naototamura additionalbenefitsofbelimumabinchronicphaseofsystemiclupuserythematosusandefficacyoftacrolimuscombinationtherapy AT shinjimorimoto additionalbenefitsofbelimumabinchronicphaseofsystemiclupuserythematosusandefficacyoftacrolimuscombinationtherapy |